 Home > Medical News > Latest Medical News > The pivotal Phase 3 clinical results of IL-2 receptor targeted therapy are positive, and the marketing application is expected to be submitted this year

The pivotal Phase 3 clinical results of IL-2 receptor targeted therapy are positive, and the marketing application is expected to be submitted this year

 Last Update: 2022-04-17
 Source: Internet
 Author: User

Tags

anastrozole breast cancer

urachal cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Citius Pharmaceuticals announced positive top-line results from a pivotal Phase 3 clinical trial of its investigational therapy I/ONTAK (E7777) in patients with persistent or relapsed cutaneous T-cell lymphoma (CTCL)

Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma

I/ONTAK is a recombinant fusion protein that combines the IL-2 receptor binding domain with a fragment of diphtheria toxin

▲The mechanism of action of I/ONTAK (Image source: Citius official website)

In this study, a total of 71 patients with persistent or recurrent CTCL were treated, and 69 patients were included in the primary efficacy analysis

▲Part of the preliminary analysis data of I/ONTAK (Image source: Reference [1])

"The results of this trial are encouraging, we believe it is clinically meaningful, and we hope that I/ONTAK will become an important treatment option for patients with persistent or relapsing CTCL,

References:

[1] Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submission.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

The pivotal Phase 3 clinical results of Express IL-2 receptor-targeted therapy are positive, and a marketing application is expected to be submitted this year

04-25

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

The pivotal Phase 3 clinical results of IL-2 receptor targeted therapy are positive, and the marketing application is expected to be submitted this year

Related Articles

The pivotal Phase 3 clinical results of Express IL-2 receptor-targeted therapy are positive, and a marketing application is expected to be submitted this year